Impact of sequential therapy with osimertinib on the overall survival in patients with EGFR-mutant non-small cell lung cancer
- Location
-
Deutsche Nationalbibliothek Frankfurt am Main
- ISSN
-
2314-8551
- Extent
-
Online-Ressource
- Language
-
Englisch
- Notes
-
online resource.
- Bibliographic citation
-
Impact of sequential therapy with osimertinib on the overall survival in patients with EGFR-mutant non-small cell lung cancer ; volume:16 ; number:1 ; day:20 ; month:3 ; year:2022 ; pages:1-7 ; date:12.2022
Egyptian journal of bronchology ; 16, Heft 1 (20.3.2022), 1-7, 12.2022
- Creator
-
Inomata, Minehiko
Matsumoto, Masahiro
Mizushima, Isami
Hayashi, Kana
Seto, Zenta
Tokui, Kotaro
Taka, Chihiro
Okazawa, Seisuke
Kambara, Kenta
Imanishi, Shingo
Miwa, Toshiro
Hayashi, Ryuji
Matsui, Shoko
Tobe, Kazuyuki
- Contributor
-
SpringerLink (Online service)
- DOI
-
10.1186/s43168-022-00121-1
- URN
-
urn:nbn:de:101:1-2022061110042060574796
- Rights
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Last update
-
15.08.2025, 7:23 AM CEST
Data provider
This object is provided by:
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Associated
- Inomata, Minehiko
- Matsumoto, Masahiro
- Mizushima, Isami
- Hayashi, Kana
- Seto, Zenta
- Tokui, Kotaro
- Taka, Chihiro
- Okazawa, Seisuke
- Kambara, Kenta
- Imanishi, Shingo
- Miwa, Toshiro
- Hayashi, Ryuji
- Matsui, Shoko
- Tobe, Kazuyuki
- SpringerLink (Online service)
Other Objects (12)
Summary of Research: Overall Survival with Osimertinib in Resected EGFR-Mutated NSCLC
Therapeutic strategies for EGFR-mutated non-small cell lung cancer patients with osimertinib resistance
Clinical efficacy of osimertinib in EGFR-mutant non-small cell lung cancer with distant metastasis
The Allele Frequency of EGFR Mutations Predicts Survival in Advanced EGFR T790M-Positive Non-small Cell Lung Cancer Patients Treated with Osimertinib
Osimertinib and palbociclib in an EGFR-mutated NSCLC with primary CDK4 amplification after progression under osimertinib
ADAURA: The Splash of Osimertinib in Adjuvant EGFR-Mutant Non-small Cell Lung Cancer
Evaluation of Cost-Effectiveness of Adjuvant Osimertinib in Patients with Resected EGFR Mutation-Positive Non-small Cell Lung Cancer
Osimertinib in Indian patients with T790M-positive advanced nonsmall cell lung cancer
Intercellular transfer of exosomal wild type EGFR triggers osimertinib resistance in non-small cell lung cancer
EGFR T790M relative mutation purity predicts osimertinib treatment efficacy in non-small cell lung cancer patients
Osimertinib in combination with anti-angiogenesis therapy presents a promising option for osimertinib-resistant non-small cell lung cancer
Combination of Crizotinib and Osimertinib in T790M+ EGFR-Mutant Non-Small Cell Lung Cancer with Emerging MET Amplification Post-Osimertinib Progression in a 10-Year Survivor: A Case Report
Summary of Research: Overall Survival with Osimertinib in Resected EGFR-Mutated NSCLC
Therapeutic strategies for EGFR-mutated non-small cell lung cancer patients with osimertinib resistance
Clinical efficacy of osimertinib in EGFR-mutant non-small cell lung cancer with distant metastasis
The Allele Frequency of EGFR Mutations Predicts Survival in Advanced EGFR T790M-Positive Non-small Cell Lung Cancer Patients Treated with Osimertinib
Osimertinib and palbociclib in an EGFR-mutated NSCLC with primary CDK4 amplification after progression under osimertinib
ADAURA: The Splash of Osimertinib in Adjuvant EGFR-Mutant Non-small Cell Lung Cancer
Evaluation of Cost-Effectiveness of Adjuvant Osimertinib in Patients with Resected EGFR Mutation-Positive Non-small Cell Lung Cancer
Osimertinib in Indian patients with T790M-positive advanced nonsmall cell lung cancer
Intercellular transfer of exosomal wild type EGFR triggers osimertinib resistance in non-small cell lung cancer
EGFR T790M relative mutation purity predicts osimertinib treatment efficacy in non-small cell lung cancer patients
Osimertinib in combination with anti-angiogenesis therapy presents a promising option for osimertinib-resistant non-small cell lung cancer
Combination of Crizotinib and Osimertinib in T790M+ EGFR-Mutant Non-Small Cell Lung Cancer with Emerging MET Amplification Post-Osimertinib Progression in a 10-Year Survivor: A Case Report
Summary of Research: Overall Survival with Osimertinib in Resected EGFR-Mutated NSCLC
Therapeutic strategies for EGFR-mutated non-small cell lung cancer patients with osimertinib resistance
Clinical efficacy of osimertinib in EGFR-mutant non-small cell lung cancer with distant metastasis
The Allele Frequency of EGFR Mutations Predicts Survival in Advanced EGFR T790M-Positive Non-small Cell Lung Cancer Patients Treated with Osimertinib
Osimertinib and palbociclib in an EGFR-mutated NSCLC with primary CDK4 amplification after progression under osimertinib
ADAURA: The Splash of Osimertinib in Adjuvant EGFR-Mutant Non-small Cell Lung Cancer
Evaluation of Cost-Effectiveness of Adjuvant Osimertinib in Patients with Resected EGFR Mutation-Positive Non-small Cell Lung Cancer
Osimertinib in Indian patients with T790M-positive advanced nonsmall cell lung cancer
Intercellular transfer of exosomal wild type EGFR triggers osimertinib resistance in non-small cell lung cancer
EGFR T790M relative mutation purity predicts osimertinib treatment efficacy in non-small cell lung cancer patients
Osimertinib in combination with anti-angiogenesis therapy presents a promising option for osimertinib-resistant non-small cell lung cancer